Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - cefalexin monohydrate, quantity: 525.76 mg (equivalent: cefalexin, qty 500 mg) - capsule, hard - excipient ingredients: magnesium stearate; microcrystalline cellulose; gelatin; purified water; titanium dioxide - treatment of the following infections when caused by susceptible strains of the designated microorganisms. respiratory tract infections. caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present). bacterial sinusitis. caused by streptococci, s. pneumoniae and s. aureus (methicillin sensitive only). otitis media. due to s. pneumoniae, staphylococci. skin and skin structure infections. caused by staphylococci and/or streptococci. genitourinary tract infections, including acute prostatitis. caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and s

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - cefalexin -

Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

kela sa-nv - cefaléxine monohydraté 263 mg - eq. céfalexine 250 mg - comprimé - 250 mg - cefaléxine monohydraté 263 mg - cefalexin - chien

Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

kela sa-nv - cefaléxine monohydraté 52,6 mg - eq. céfalexine 50 mg - comprimé - 50 mg - cefaléxine monohydraté 52.6 mg - cefalexin - chien

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - cefalexin monohydrate, quantity: 52.576 mg/ml (equivalent: cefalexin, qty 50 mg/ml) - suspension, powder for - excipient ingredients: sodium benzoate; simethicone; iron oxide yellow; citric acid; sucrose; saccharin sodium; guar galactomannan; flavour - treatment of the following infections when caused by susceptible strains of the designated microorganisms. respiratory tract infections. caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present). bacterial sinusitis. caused by streptococci, s. pneumoniae and s. aureus (methicillin sensitive only). otitis media. due to s. pneumoniae, staphylococci. skin and skin structure infections. caused by staphylococci and/or streptococci. genitourinary tract infections, including acute prostatitis. caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and s

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - cefalexin monohydrate, quantity: 26.288 mg/ml (equivalent: cefalexin, qty 25 mg/ml) - suspension, powder for - excipient ingredients: sodium benzoate; guar galactomannan; iron oxide yellow; saccharin sodium; citric acid; simethicone; sucrose; flavour - treatment of the following infections when caused by susceptible strains of the designated microorganisms. respiratory tract infections. caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present). bacterial sinusitis. caused by streptococci, s. pneumoniae and s. aureus (methicillin sensitive only). otitis media. due to s. pneumoniae, staphylococci. skin and skin structure infections. caused by staphylococci and/or streptococci. genitourinary tract infections, including acute prostatitis. caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and s

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - cefalexin monohydrate, quantity: 550 mg (equivalent: cefalexin, qty 500 mg) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate; gelatin; titanium dioxide; iron oxide yellow; brilliant blue fcf; sunset yellow fcf; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of the following bacterial infections when caused by susceptible strains of the designated micro-organisms. respiratory tract infections; strep. pneumoniae and group a b-haemolytic streptococci. although penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections (including the prophylaxis of rheumatic fever), cephalexin is generally effective in the eradication of streptococci from the nasopharynx. substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present. bacterial sinusitis: streptococci, strep. pneumoniae and staph. aureus (methicillin sensitive only). otitis media: strep. pneumoniae, staphylococci (methicillin sensitive only). skin and skin structure infections: staphylococci (methicillin sensitive only) and/or streptococci. genitourinary tract infections, including acute prostatitis: e.coli, p.mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and noumed cephalexin is not indicated in these conditions. note. appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to noumed cephalexin. renal function studies should be perfomed when indicated.

Brasil - portugisisk - ANVISA (Agência Nacional de Vigilância Sanitária)

fundaÇÃo para o remÉdio popular - furp - cefalexina, cefalexina monoidratada - cefalosporinas

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

flynn pharma ltd - cefalexin - oral tablet - 500mg

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios normon s.a. - cefalexina monohidrato - cÁpsula dura - 500 mg - cefalexina monohidrato 500 mg - cefalexina